Hemodynamic Behavior of SS RBC in the Ex Vivo Mesocecum Vasculature: Protective Effect of Anionic Polysaccharides on TSP-Enhanced Peripheral Resistance (PRU) and Pressure-Flow Recovery Times (Tpf)
| Experimental Group . | Treatment . | n . | ΔPRU (% increase) . | ΔΔPRU . | Tpf (sec) . |
|---|---|---|---|---|---|
| 1 | i. None | 3 | 24.8 ± 5.6 | 100.0 ± 5.6 | 73.3 ± 5.8 |
| ii. TSP | 3 | 51.7 ± 9.9* | 208.5 ± 16.7 | 113.3 ± 7.6* | |
| iii. CSA/TSP | 3 | 26.2 ± 5.02-153 | 105.8 ± 10.2 | 80.0 ± 5.0‡ | |
| 2 | i. None | 4 | 29.9 ± 3.9 | 100.0 ± 3.9 | 70.0 ± 17.8 |
| ii. TSP | 4 | 67.2 ± 16.82-153 | 222.0 ± 32 | 97.5 ± 12.6* | |
| iii. HS/TSP | 4 | 53.7 ± 21.8 | 151.3 ± 22.9 | 87.5 ± 11.9 | |
| 3 | i. None | 5 | 32.8 ± 11.0 | 100.0 ± 11.0 | 80.0 ± 26.5 |
| ii. TSP | 5 | 61.1 ± 20.5* | 181.8 ± 19.1 | 107 ± 32.1† | |
| iii. Heparin/TSP | 5 | 40.6 ± 16.1‡ | 122.5 ± 19.3 | 84.0 ± 24.6‡ | |
| 4 | i. None | 4 | 30.2 ± 11.3 | 100.0 ± 11.3 | 80.0 ± 16.3 |
| ii. TSP | 4 | 42.4 ± 17.8* | 142.7 ± 6.7 | 106.7 ± 22.6* | |
| iii. HDS/TSP | 4 | 25.9 ± 11.52-153 | 87.2 ± 10.2 | 82.5 ± 27.52-153 | |
| 5 | i. None | 3 | 31.1 ± 7.3 | 100.0 ± 7.3 | 71.7 ± 7.6 |
| ii. TSP | 3 | 59.7 ± 13.6* | 195.6 ± 38.1 | 168.3 ± 7.6† | |
| iii. FUC/TSP | 3 | 51.4 ± 6.9 | 174.6 ± 60.4 | 105.0 ± 26.0 |
| Experimental Group . | Treatment . | n . | ΔPRU (% increase) . | ΔΔPRU . | Tpf (sec) . |
|---|---|---|---|---|---|
| 1 | i. None | 3 | 24.8 ± 5.6 | 100.0 ± 5.6 | 73.3 ± 5.8 |
| ii. TSP | 3 | 51.7 ± 9.9* | 208.5 ± 16.7 | 113.3 ± 7.6* | |
| iii. CSA/TSP | 3 | 26.2 ± 5.02-153 | 105.8 ± 10.2 | 80.0 ± 5.0‡ | |
| 2 | i. None | 4 | 29.9 ± 3.9 | 100.0 ± 3.9 | 70.0 ± 17.8 |
| ii. TSP | 4 | 67.2 ± 16.82-153 | 222.0 ± 32 | 97.5 ± 12.6* | |
| iii. HS/TSP | 4 | 53.7 ± 21.8 | 151.3 ± 22.9 | 87.5 ± 11.9 | |
| 3 | i. None | 5 | 32.8 ± 11.0 | 100.0 ± 11.0 | 80.0 ± 26.5 |
| ii. TSP | 5 | 61.1 ± 20.5* | 181.8 ± 19.1 | 107 ± 32.1† | |
| iii. Heparin/TSP | 5 | 40.6 ± 16.1‡ | 122.5 ± 19.3 | 84.0 ± 24.6‡ | |
| 4 | i. None | 4 | 30.2 ± 11.3 | 100.0 ± 11.3 | 80.0 ± 16.3 |
| ii. TSP | 4 | 42.4 ± 17.8* | 142.7 ± 6.7 | 106.7 ± 22.6* | |
| iii. HDS/TSP | 4 | 25.9 ± 11.52-153 | 87.2 ± 10.2 | 82.5 ± 27.52-153 | |
| 5 | i. None | 3 | 31.1 ± 7.3 | 100.0 ± 7.3 | 71.7 ± 7.6 |
| ii. TSP | 3 | 59.7 ± 13.6* | 195.6 ± 38.1 | 168.3 ± 7.6† | |
| iii. FUC/TSP | 3 | 51.4 ± 6.9 | 174.6 ± 60.4 | 105.0 ± 26.0 |
The values are mean ± SD. ΔPRU represents percent increase in PRU following infusion of RBC compared with pre-infusion PRU for the preparation; ΔΔPRU represents percent changes after control values are normalized to 100%; Tpf, pressure-flow recovery time to the baseline level. In these experiments, SS RBC were either untreated, incubated with TSP (2.5 μg/ml) or treated sequentially with given anionic polysaccharide (250 μg/ml) and TSP (2.5 μg/ml) as described in Materials and Methods.
P < .05-.02 and
P < .01 (paired t-test) compared with control (None).
P < .05 and
P < .01 (paired t-test) compared with TSP.